Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Oncobiologics (OTLK) delivered earnings and revenue surprises of -4.76% and -40.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?